HEPA Hepion Pharma Total Asset Value of Company

The price history of Hepion Pharmaceuticals (HEPA) demonstrates total assets at 0.00. The business relies on a unique drug capable of halting liver tissue scarring. Growth potential is based on demand from insurance funds within the organ obesity combat segment. However, the company is currently experiencing an acute crisis due to failed tests, forcing management to seek buyers or liquidate capital.

HEPA (Hepion Pharmaceuticals, Inc.) Company Total Assets history from 07/04/2022 to 06/14/2025

Analytical breakdowns and data insights for company hepionpharma.com (HEPA)

- market value and analyst target forecast:

Stock Price Hepion Pharmaceuticals, Inc.|HEPA - Price Target Chart

- market capitalization data:

Market Valuation Hepion Pharmaceuticals, Inc.|HEPA - Enterprise Value

- issuer book value statistics:

Accounting Value of a Share Hepion Pharmaceuticals|HEPA - Book Capitalization|Market Capitalization to Book Value Ratio hepionpharma.com|HEPA - Aggregate Company Assets

- debt burden and liquidity indicators:

All Debt to Shareholders' Equity Ratio Hepion Pharmaceuticals|HEPA - Long-Term Debt to Equity|Short-Term Debt to Equity Ratio Hepion Pharmaceuticals, Inc.|HEPA - Company Aggregate Debts|Debts to Book Capitalization Hepion Pharmaceuticals, Inc.|HEPA - Company Long-Term Liabilities|Company Short-Term Loans and Borrowings Hepion Pharmaceuticals|Quick Liquidity hepionpharma.com

- net income and valuation multiples indicators:

HEPA - Net Profit

Fundamental valuation:Hepion Pharmaceuticals

Manufactured products of Hepion Pharmaceuticals Inc.

Total assets, reverse-calculated via ROA, reflect the aggregate resource potential of Hepion Pharmaceuticals (HEPA), allowing for an assessment of capital management efficiency amid expensive debt financing. By analyzing the total asset forecast for Hepion Pharmaceuticals (HEPA), an investor can see how colossal R&D expenditures and patent protection within the strict FDA regulatory environment impact the balance sheet, necessitating a rigorous correlation between base growth and actual returns.

Key competitors

arrowheadpharma.com (ARWR) - Company Total Assets|Aggregate Company Assets Mirum|Dynavax - Total Asset Value of Company|Company Total Assets ABUS|IVA (Inventiva Corp) - Aggregate Asset Value|Company Total Assets GYRE (Gyre Therapeutics, Inc.)|Company Total Assets assemblybio.com ASMB|GALT - Aggregate Company Assets|Aggregate Asset Value GNFT (Genfit S.A.)|durect.com (DRRX) - Aggregate Company Assets|Cumulative Company Assets Aligos Therapeutics, Inc.|BIVI (BioVie Inc) - Company Total Assets|Company Total Assets Galmed Pharma|Cumulative Company Assets NDRA (ENDRA Life Sciences Inc.)